Overview

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
Phase:
Phase 2
Details
Lead Sponsor:
Italian Sarcoma Group
Collaborator:
PharmaMar
Treatments:
Trabectedin